June 9 (Reuters) - Avidity Biosciences Inc RNA.O:
AVIDITY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE PHASE 1/2 FORTITUDE™ DATA DEMONSTRATING CONSISTENT IMPROVEMENT ACROSS MULTIPLE FUNCTIONAL MEASURES COMPARED TO PLACEBO IN DEL-BRAX TREATED FSHD PARTICIPANTS
AVIDITY BIOSCIENCES INC - DATA SUPPORT PLANNED ACCELERATED APPROVAL BLA SUBMISSION IN H2 2026
Source text: ID:nPn4d9Kyra
Further company coverage: RNA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.